Novo Nordisk invests €2.1bn in production expansion
In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.<br /><br /><br />
In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.<br /><br /><br />
Flagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.
Finnish protein maker Solar Foods has closed an oversubscribed €8M Series B financing and will expand Solein protein production and support the construction of a commercial production plant.
The Budget Committee of the German Bundestag has announced to channel €38m in funding into the sustainable protein transition next year.<br /><br />
German precision fermentation specialist MicroHarvest GmbH has launched a single-cell protein pilot plant in Lison with an initial capacity of 25kg per day.
The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testing.
<p itemprop="headline">Dutch VectorY Tx BV has closed one of this yers’s largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.</p>
Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.
The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already […]
Belgian amyloid fibrils specialist Amyl Therapeutics SA has got a �11n cash injection by existing and new investors and the Walloon region to advance its therapeutic platform. <br /> <br /><br […]